Artiva Biotherapeutics Files Q2 2024 10-Q

TL;DR

**Artiva Biotherapeutics files Q2 2024 10-Q, detailing financial performance and operational updates.**

AI Summary

Artiva Biotherapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operations. Key financial data and operational highlights for the second quarter of 2024 are detailed within the filing.

Why It Matters

This filing provides investors with a detailed look at Artiva Biotherapeutics' financial health and operational progress during the second quarter of 2024, crucial for investment decisions.

Risk Assessment

Risk Level: medium — As a biotechnology company, Artiva Biotherapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• Q2 2024 — Reporting Period (Financial results for the second quarter of 2024 are presented.)
• 2024-01-01 to 2024-06-30 — Period Covered (This 10-Q covers the first six months of 2024.)

Key Players & Entities

• Artiva Biotherapeutics, Inc. (company) — Filer of the 10-Q
• 20240630 (date) — End of the reporting period
• 20240829 (date) — Filing date of the 10-Q
• 5505 MOREHOUSE DRIVE, SAN DIEGO, CA 92121 (address) — Company's business and mailing address

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share ARTV The Nasdaq Global Ma

Filing Documents

• d705006d10q.htm (10-Q) — 1758KB
• d705006dex311.htm (EX-31.1) — 9KB
• d705006dex312.htm (EX-31.2) — 9KB
• d705006dex321.htm (EX-32.1) — 6KB
• 0001193125-24-209924.txt ( ) — 7198KB
• ck0001817241-20240630.xsd (EX-101.SCH) — 59KB
• ck0001817241-20240630_cal.xml (EX-101.CAL) — 41KB
• ck0001817241-20240630_def.xml (EX-101.DEF) — 298KB
• ck0001817241-20240630_lab.xml (EX-101.LAB) — 432KB
• ck0001817241-20240630_pre.xml (EX-101.PRE) — 375KB
• d705006d10q_htm.xml (XML) — 1028KB

- Financial Information

Part I - Financial Information 6

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) 6 Condensed Balance Sheets 6 Condensed Statements of Operations and Comprehensive Loss 7 Condensed Statements of Convertible Preferred Stock and Stockholders' Deficit 8 Condensed Statements of Cash Flows 9 Notes to Condensed Financial Statements 10

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 29

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 41

Controls and Procedures

Item 4. Controls and Procedures 41

- Other Information

Part II - Other Information 42

Legal Proceedings

Item 1. Legal Proceedings 42

Risk Factors

Item 1A. Risk Factors 42

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 109

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 110

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 110

Other Information

Item 5. Other Information 110

Exhibits

Item 6. Exhibits 110

Signatures

Signatures 112 3 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding future events, our business strategy, and the plans and objectives of management for future operations, are forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would," or the negative of these words or other similar terms or expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about: the success, cost, timing and potential indications of our product development activities and clinical trials, including the ongoing clinical trials of AlloNK; the timing of our planned Investigational New Drug application (IND) submissions to the United States Food and Drug Administration (FDA) for our product candidates, including AlloNK; the timing of the initiation, enrollment and completion of planned clinical trials; the ability to obtain regulatory approval for our manufacturing facility in San Diego, California and the cost and timing associated therewith; our ability to obtain and maintain regulatory approval of our product candidates, including AlloNK, in any of the i

- Financial Information

Part I - Financial Information Item1. Financial Statements ARTIVA BIOTHERAPEUTICS, INC. Condensed Balance Sheets (Unaudited) (in thousands, except share and par value data) AS OF JUNE 30, 2024 DECEMBER 31, 2023 Assets Current assets: Cash and cash equivalents $ 34,248 $ 53,504 Short-term investments 12,308 23,467 Accounts receivable (including related party amounts of $ 569 and $ 569 , respectively) 569 1,034 Other receivables (including related party amounts of $ 700 and $ 607 , respectively) 892 724 Prepaid expenses and other current assets 1,732 1,092 Total current assets 49,749 79,821 Restricted cash 258 258 Property and equipment, net 7,315 8,096 Operating lease right-of-use assets 15,129 16,547 Financing lease right-of-use asset 291 — Deferred offering costs 2,840 — Other long-term assets 330 392 Total assets $ 75,912 $ 105,114 Liabilities, convertible preferred stock, and stockholders' deficit Current liabilities: Accounts payable (including related party amounts of $ 223 and $ 199 , respectively) $ 823 $ 614 Accrued expenses (including related party amounts of $ 859 and $ 2,161 , respectively) 6,214 8,017 Current portion of operating lease liabilities 3,674 3,596 Current portion of financing lease liability 116 — Total current liabilities 10,827 12,227 Operating lease liabilities, net of current portion 11,869 13,316 Financing lease liability, net of current portion 106 — Simple agreements for future equity ("SAFEs") (including related party amounts of $ 22,427 and $ 20,315 , respectively) 27,720 25,100 Other non-current liabilities 74 73 Total liabilities 50,596 50,716 Commitments and contingencies (Note 11) Series A convertible preferred stock, $ 0.0001 par value; 16,110,463 shares authorized; 3,673,148 issued and outstanding at June 30, 2024 and December 31, 2023; $ 80,552 aggregate liquidation preference at June

View Full Filing

View this 10-Q filing on SEC EDGAR